We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.94%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.45B
AUM Growth
+$719M
Cap. Flow
+$643M
Cap. Flow %
6.8%
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21

Top Buys

Rank Stock Value
1
ACCD
Accolade Inc
ACCD
+$56.6M
2
RVMD icon
Revolution Medicines
RVMD
+$46M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$43.7M
4
EPIX
ESSA Pharma
EPIX
+$42.4M
5
BDX icon
Becton Dickinson
BDX
+$33.4M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$86.9M
2
HALO icon
Halozyme
HALO
+$47.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$38.1M
4
ESPR
Esperion Therapeutics
ESPR
+$33.9M
5
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$33.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.93%
2 Industrials 0.88%
3 Technology 0.47%
4 Consumer Discretionary 0.04%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELL
101
DELISTED
PhenomeX Inc. Common Stock
CELL
$19M 0.2%
379,003
+218,498
+136% +$14.9M
VCRA
102
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$18.9M 0.2%
492,107
+223,936
+84% +$9.65M
LEGN icon
103
Legend Biotech
LEGN
$4.3B
$17.5M 0.19%
603,243
+186,902
+45% +$5.1M
RMD icon
104
ResMed
RMD
$28.3B
$17.1M 0.18%
88,145
-10,830
-11% -$2.17M
REGN icon
105
Regeneron Pharmaceuticals
REGN
$68.8B
$16.9M 0.18%
35,800
+8,100
+29% +$3.94M
TMO icon
106
Thermo Fisher Scientific
TMO
$211B
$16.7M 0.18%
36,574
-7,881
-18% -$3.76M
QTTB icon
107
Q32 Bio
QTTB
$450M
$16.3M 0.17%
96,507
– –
AMED
108
DELISTED
Amedisys
AMED
$16M 0.17%
60,487
-10,703
-15% -$3.02M
AVTR icon
109
Avantor
AVTR
$7.81B
$14.8M 0.16%
512,216
– –
INGN icon
110
Inogen
INGN
$167M
$14.8M 0.16%
280,863
+101,720
+57% +$5.08M
WVE icon
111
Wave Life Sciences
WVE
$1.12B
$14.6M 0.15%
2,602,858
– –
OM icon
112
Outset Medical
OM
$74.9M
$13.9M 0.15%
17,048
+4,401
+35% +$3.4M
GTH
113
DELISTED
Genetron Holdings Limited ADS
GTH
$13.6M 0.14%
210,696
+152,413
+262% +$10.5M
CDNA icon
114
CareDx
CDNA
$1.92B
$13M 0.14%
190,371
-153,612
-45% -$11.9M
XENT
115
DELISTED
Intersect ENT, Inc
XENT
$12.9M 0.14%
617,968
-1,513
-0.2% -$34.9K
OSCR icon
116
Oscar Health
OSCR
$8.5B
$12.2M 0.13%
+454,574
New +$14.2M
IRTC icon
117
iRhythm Holdings
IRTC
$3.59B
$12.2M 0.13%
87,631
-10,971
-11% -$1.97M
BNR
118
Burning Rock Biotech
BNR
$11.7M 0.12%
43,293
+24,764
+134% +$7.54M
ZLAB icon
119
Zai Lab
ZLAB
$2.17B
$11.5M 0.12%
86,500
+53,800
+165% +$8.33M
TRHC
120
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$10.5M 0.11%
227,178
+9,203
+4% +$439K
XRAY icon
121
Dentsply Sirona
XRAY
$2.59B
$10.2M 0.11%
159,129
– –
NBP
122
NovaBridge Biosciences American Depositary Shares
NBP
$205M
$9.62M 0.1%
198,457
-4,755
-2% -$258K
CVS icon
123
CVS Health
CVS
$137B
$9.37M 0.1%
124,548
+3,953
+3% +$288K
LUNG icon
124
Pulmonx
LUNG
$49.4M
$8.07M 0.09%
176,510
– –
GILD icon
125
Gilead Sciences
GILD
$161B
$7.17M 0.08%
111,000
+26,400
+31% +$1.7M
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2021 Portfolio in Review

As of Q1 2021, Bellevue Group held 237 positions worth $9.45B, up 8.2% from $8.73B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $643M of net new capital in Q1 2021, opening 15 new positions and adding to 96 existing holdings. Its largest new stake was ESSA Pharma: 1,825,814 shares worth $53M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $86.9M trimmed.

  • Bellevue Group's largest Q1 2021 buy was ESSA Pharma: 1,825,814 shares worth $53M.
  • Bellevue Group added most to Accolade Inc in Q1 2021, an estimated $56.6M increase.
  • Bellevue Group's biggest Q1 2021 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $86.9M.
  • Bellevue Group fully exited GenMark Diagnostics, Inc in Q1 2021, selling an estimated $38.1M.
  • Bellevue Group's ten largest holdings make up 29% of its $9.45B portfolio in Q1 2021.
  • Bellevue Group opened 15 new positions and closed 21 in Q1 2021.
  • Bellevue Group's portfolio value rose 8.2% quarter-over-quarter to $9.45B.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.